| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
mRNA
The target is the eukaryotic translation initiation machinery, specifically the initiation factor eIF4E. During mRNA translation, the cap binds to eIF4E, recruiting the ribosome. This cap analogue mimics the natural 5' cap of eukaryotic mRNA. The LNA component increases its stability and resistance to decapping enzymes, enhancing the efficiency of translation. |
|---|---|
| ln Vitro |
In vitro, 3'Ome-m7GpppAmpG ammonium shows a significant translational efficiency. In cell-free translation systems (e.g., rabbit reticulocyte lysate), mRNA transcripts capped with this analogue produce substantially higher yields of protein compared to uncapped mRNA or those capped with standard analogues. This demonstrates its superior biological activity.
|
| ln Vivo |
In vivo, this cap analogue is used to generate synthetic mRNA for therapeutic applications. In animal models, mRNA modified with this cap shows prolonged protein expression and enhanced stability. This is crucial for mRNA vaccines where high antigen production is required. The cap itself is not therapeutic, but it enables mRNA therapeutics.
|
| Enzyme Assay |
No enzyme/receptor binding assays are performed. The quality of the capped RNA is confirmed by denaturing agarose gel electrophoresis and its translational efficiency is tested in a cell-free translation system. For quality control, the cap analogue can be analyzed by HPLC to verify its purity and chemical integrity.
|
| Cell Assay |
In cell-based assays, cells are transfected with synthetic mRNA capped with 3'Ome-m7GpppAmpG ammonium using lipid nanoparticles or electroporation. After 6-24 hours, protein expression is measured by Western blot, flow cytometry, or ELISA. This confirms that the cap analogue facilitates high-efficiency protein production from the delivered mRNA.
|
| Animal Protocol |
In vivo efficacy of the cap analogue is tested in animal models (e.g., mice). Animals are injected with mRNA (formulated in lipid nanoparticles) encoding a reporter protein (e.g., luciferase or GFP). Bioluminescence imaging or tissue analysis quantifies protein expression over time. Animals receiving mRNA capped with this analogue show higher and more sustained protein expression compared to uncapped controls.
|
| ADME/Pharmacokinetics |
The analogue is provided as a 100 mM solution in deionized water. For storage, the solution should be kept at -20degC to prevent degradation. It is stable for up to 6 months at -80degC. The cap analogue is co-transcriptionally incorporated into RNA using T7 RNA polymerase, replacing the standard cap analog in the transcription reaction mix.
|
| Toxicity/Toxicokinetics |
As a molecular biology reagent, toxicity data is not applicable. The cap analogue is not administered directly to patients in its current form; it is incorporated into synthetic mRNA. The TFA salt is not intended for human consumption. Standard laboratory safety precautions for handling nucleic acids should be followed.
|
| References |
[1]. Senthilvelan A, et al. Trinucleotide Cap Analogue Bearing a Locked Nucleic Acid Moiety: Synthesis, mRNA Modification, and Translation for Therapeutic Applications. Org Lett. 2021 Jun 4;23(11):4133-4136.
|
| Additional Infomation |
This product is a research-grade chemical tool for advanced molecular biology applications. It has been explored as a potential tool in mRNA vaccines and mRNA transfection, including protein production, gene therapy, and anti-cancer immunization. It is not a drug and has no FDA approval for human therapy.
|
| Molecular Formula |
C33H45N15O24P4.XNH3
|
|---|---|
| Related CAS # |
3'Ome-m7GpppAmpG;2089461-55-0
|
| Appearance |
Colorless to light yellow liquid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
